CYP3A4*22 and bleeding risk in ticagrelor users.

A study published in the journal Basic & Clinical Pharmacology & Toxicology examined the relationship between genetic variations and bleeding risk in patients using the medication ticagrelor. The study analyzed data from Finnish and UK biobanks and found that one genetic variant, CYP3A4*22, was associated with an increased risk of bleeding in ticagrelor users. However, two other genetic variations, CYP3A5*3 and CYP4F2 rs3093135, were not found to be associated with bleeding risk. The study's findings contribute to our understanding of the pharmacogenetics of ticagrelor and its potential side effects. It is important to consider the limitations of the study, such as the reliance on prescription records, which may not accurately reflect actual drug use. [Extracted from the article]